Impact of an Angiotensin Receptor Blocker in Aortic Stenosis (ARBAS) – A Randomized Controlled Trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518389-28-00

Acronym

ARBAS041218

Enrollment

139

Registered

2025-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic stenosis

Brief summary

The rate of progression of peak aortic velocity (m/s) assessed by echocardiography, The rate of progression of aortic valve calcification (AU) assessed by non-contrast computed tomography after 24 months treatment with losartan compared with placebo.

Detailed description

Left ventricular geometry and mass (relative wall-thickness, left ventricular mass index) assessed by echocardiography and magnetic resonance imaging after 24 months treatment with losartan compared with placebo treatment., Diastolic function assessed by echocardiography, Markers of left ventricular filling pressures (E/e’, NT-proBNP)

Interventions

DRUGPLACEBO

DRUGLOSARTAN POTASSIUM

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The rate of progression of peak aortic velocity (m/s) assessed by echocardiography, The rate of progression of aortic valve calcification (AU) assessed by non-contrast computed tomography after 24 months treatment with losartan compared with placebo.	—

Secondary

Measure	Time frame
Left ventricular geometry and mass (relative wall-thickness, left ventricular mass index) assessed by echocardiography and magnetic resonance imaging after 24 months treatment with losartan compared with placebo treatment., Diastolic function assessed by echocardiography, Markers of left ventricular filling pressures (E/e’, NT-proBNP)	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026